These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
53 related articles for article (PubMed ID: 18303482)
21. Novel cancer therapies: treatments driven by tumour biology. Ramaswami R; Harding V; Newsom-Davis T Postgrad Med J; 2013 Nov; 89(1057):652-8. PubMed ID: 24129032 [TBL] [Abstract][Full Text] [Related]
22. Novel biological agents for the treatment of hormone-refractory prostate cancer (HRPC). Papatsoris AG; Karamouzis MV; Papavassiliou AG Curr Med Chem; 2005; 12(3):277-96. PubMed ID: 15723619 [TBL] [Abstract][Full Text] [Related]
23. Co-targeting driver pathways in prostate cancer: two birds with one stone. Zoubeidi A; Gleave ME EMBO Mol Med; 2018 Apr; 10(4):. PubMed ID: 29572264 [TBL] [Abstract][Full Text] [Related]
24. Molecularly targeted agents as radiosensitizers in cancer therapy--focus on prostate cancer. Alcorn S; Walker AJ; Gandhi N; Narang A; Wild AT; Hales RK; Herman JM; Song DY; Deweese TL; Antonarakis ES; Tran PT Int J Mol Sci; 2013 Jul; 14(7):14800-32. PubMed ID: 23863691 [TBL] [Abstract][Full Text] [Related]
25. A multidisciplinary approach to the management of hormone-refractory prostate cancer. Taneja SS Rev Urol; 2003; 5 Suppl 3(Suppl 3):S85-91. PubMed ID: 16985956 [TBL] [Abstract][Full Text] [Related]
26. A multidisciplinary approach to the management of hormone-refractory prostate cancer. Taneja SS Rev Urol; 2003; 5 Suppl 2(Suppl 2):S53-9. PubMed ID: 16986048 [TBL] [Abstract][Full Text] [Related]
28. Targeting and killing of metastatic cells in the transgenic adenocarcinoma of mouse prostate model with vesicular stomatitis virus. Moussavi M; Tearle H; Fazli L; Bell JC; Jia W; Rennie PS Mol Ther; 2013 Apr; 21(4):842-8. PubMed ID: 23337981 [TBL] [Abstract][Full Text] [Related]
29. Bioengineered viral vectors for targeting and killing prostate cancer cells. Zhang KX; Jia W; Rennie PS Bioeng Bugs; 2010; 1(2):92-6. PubMed ID: 21326934 [TBL] [Abstract][Full Text] [Related]
30. Discovery and SAR exploration of N-aryl-N-(3-aryl-1,2,4-oxadiazol-5-yl)amines as potential therapeutic agents for prostate cancer. Krasavin M; Rufanov KA; Sosnov AV; Karapetian R; Godovykh E; Soldatkina O; Lavrovsky Y; Gakh AA Chem Cent J; 2010 Mar; 4():4. PubMed ID: 20214785 [TBL] [Abstract][Full Text] [Related]
31. Cell signaling modifiers in prostate cancer. Chen FL; Armstrong AJ; George DJ Cancer J; 2008; 14(1):40-5. PubMed ID: 18303482 [TBL] [Abstract][Full Text] [Related]
32. Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway. Nahta R; O'Regan RM Clin Breast Cancer; 2010 Nov; 10 Suppl 3():S72-8. PubMed ID: 21115425 [TBL] [Abstract][Full Text] [Related]
34. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck. Le Tourneau C; Siu LL Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623 [TBL] [Abstract][Full Text] [Related]
35. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity. deGraffenried LA; Friedrichs WE; Russell DH; Donzis EJ; Middleton AK; Silva JM; Roth RA; Hidalgo M Clin Cancer Res; 2004 Dec; 10(23):8059-67. PubMed ID: 15585641 [TBL] [Abstract][Full Text] [Related]